# MLN8237 in Head and Neck Cancer

> **NCT01540682** · PHASE1 · COMPLETED · sponsor: **Abramson Cancer Center at Penn Medicine** · enrollment: 9 (estimated)

## Conditions studied

- Head and Neck Cancer

## Interventions

- **DRUG:** MLN8237
- **DRUG:** Cetuximab
- **RADIATION:** Radiotherapy

## Key facts

- **NCT ID:** NCT01540682
- **Lead sponsor:** Abramson Cancer Center at Penn Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-02
- **Primary completion:** 2015-11
- **Final completion:** —
- **Target enrollment:** 9 (ESTIMATED)
- **Last updated:** 2018-08-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01540682

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01540682, "MLN8237 in Head and Neck Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01540682. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*